Table 3 Clinical trials with BTK-inhibitors in solid tumors
From: Role of Bruton’s tyrosine kinase in B cells and malignancies
BTK-inhibitor | Tumor Type | Treatment combination | Phase Trial | Status | NCT# |
|---|---|---|---|---|---|
Ibrutinib | Pancreatic Cancer | nab-paclitaxel and gemcitabine | ll/lll | Ongoing, Not Recruiting | NCT024B6668 |
Ibrutinib | Pancreatic Cancer | nab-paclitaxel and gemcitabine | I | Recruiting | NCT02562898 |
Ibrutinib | Renal/Urethelial/Gastric/Colorectal Cancer | chemotherapy/small molecule | Ib/II | Recruiting | NCT02599B24 |
Ibrutinib | HER2/MYC + Oesophageal Cancer | I | Recruiting | NCT02884453 | |
Ibrutinib | EGFR + Non-small Cell Lung Cancer (NSCLC) | I/ll | Ongoing, Not Recruiting | NCT02321540 | |
Ibrutinib | NSCLC/Breast Cancer/Pancreatic Cancer | Durvalumab (anti-PD-L1) | I/ll | Completed | NCT02403271 |
Ibrutinib | Pancreatic Neuro-endocrine tumors (pNET) /metastatic Carcinoid | II | Recruiting | NCT02575300 | |
Ibrutinib | Stage IV Cutaneous Melanoma | II | Recruiting | NCT02581930 | |
Ibrutinib | Metastatic Renal Cancer | Nivolumab (anti-PD-L1) | lb./ll | Recruiting | NCT02899078 |
Ibrutinib | Localized Prostate Cancer | I/II | Recruiting | NCT02643667 | |
Acalabrutinib | Advanced/Metastatic Pancreatic Cancer | Pembrolizumab (anti-PD-L1) | II | Ongoing, Not Recruiting | NCT02362048 |
Acalabrutinib | Recurrent Ovarian Cancer | Pembrolizumab (anti-PD-L1) | II | Ongoing, Not Recruiting | NCT02537444 |
Acalabrutinib | Glioblastoma | lb/ll | Recruiting | NCT02586857 | |
Acalabrutinib | NSCLC | Pembrolizumab (anti-PD-L1) | II | Ongoing, Not Recruiting | NCT02448303 |
Acalabrutinib | Head and Neck Squamous Cell Carcinoma (HNSCC) | Pembrolizumab (anti-PD-L1) | II | Ongoing, Not Recruiting | NCT02454179 |
Acalabrutinib | Platinum-resistant Urethelial (Bladder) Cancer | Pembrolizumab (anti-PD-L1) | II | Ongoing, Not Recruiting | NCT02351739, |